FindTrial
Sign In

Oocyte Vitrification Aided With Latrunculin A

Latrunculin A for Oocyte Vitrification

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03678571
Enrollment
400
Registered
2018-09-19
Start date
2018-09-25
Completion date
2019-07-15
Last updated
2019-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Brief summary

Using cytoskeleton Stabilizer the Latrunculin A would improve the outcome of oocyte vitrification

Interventions

OTHERLatrunculin A supplemented vitrification medium

Vitrification of human oocyte in medium supplemented with Latrunculin A

Sponsors

Banoon IVF Center
CollaboratorOTHER
Ibn Sina Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 42 Years
Healthy volunteers
No

Inclusion criteria

* indication for oocyte cryopreservation

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frame
survival after thawing6 days after thawing

Secondary

MeasureTime frameDescription
Rates of blastocyst formation and quality6 days of cultureNumber of formed blastocyst and high-quality blastocysts per fertilized oocytes
embryo utilization rate6 days of cultureNumber of utilized embryos per fertilized oocytes
clinical pregnancy ratethree monthsNumber of pregnant women with fetal pulsation per recruited cycles
ongoing pregnancy rate12 months—
fertilization rate6 days of culture—

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026